Abstract
Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.
| Original language | English |
|---|---|
| Pages (from-to) | 1050-1065 |
| Number of pages | 16 |
| Journal | ACS Pharmacology and Translational Science |
| Volume | 4 |
| Issue number | 3 |
| Early online date | 15 Apr 2021 |
| DOIs | |
| Publication status | Published - 11 Jun 2021 |
Keywords
- Multiple myeloma
- Drug resistance
- ABC transporters
- SLC transporters
- multiple myeloma
- drug resistance